Strides arm commences construction of $ 60-mn Malaysia plant

Stelis Biopharma, a wholly-owned arm of Strides Arcolab, has commenced construction of its Rs 370 crore (USD 60 million) biologics facility at Malaysia.

Stelis has entered into a build and lease agreement with Bio-XCell for the construction of 140,000 sq foot facility at Johor, Malaysia which is expected to be completed in next 24 months, Strides Arcolab said in a statement.

The facility will incorporate next-gen single-use bio-processing technology with both mammalian and microbial manufacturing suites, it added.

Stelis Biopharma CEO Joe Thomas said: "With its strong commitment to bio-economy, attractive incentives, quality infrastructure and enabling ecosystem, we are confident of making this our bio-manufacturing hub for regional and global markets".
 

The facility will employ 180 people in R&D and manufacturing.